checkAd
    Startseite > Aktien > Bausch Health Companies > Nachrichten
    Bausch Health Companies Aktie
    6,3420
     
    EUR
    -2,60 %
    -0,1690 EUR
    Letzter Kurs 17.05.24 Tradegate
    6,1950
     
    EUR
    540 STK
    Geldkurs 17.05.24
    6,2500
     
    EUR
    530 STK
    Briefkurs 17.05.24
    ISIN: CA0717341071 · WKN: A2JQ1X · SYM: BVF · Kanada

    Neueste Nachrichten

    Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
    17.05.24 · Accesswire · Bausch Health Companies
    Bausch Health Announces 2024 Annual Meeting of Shareholder Results
    15.05.24 · Accesswire · Bausch Health Companies
    Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
    14.05.24 · Accesswire · Bausch Health Companies
    Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
    09.05.24 · Accesswire · Bausch Health Companies
    Bausch Health Announces First Quarter 2024 Results
    02.05.24 · Accesswire · Bausch Health Companies
    Fokus Aktien mit extremen Handelsvolumen am Donnerstag, den 25.04.2024
    25.04.24 · wO Chartvergleich · BAVARIA Industries Group Akt
    Bausch Health to Announce First-Quarter 2024 Results on May 2
    11.04.24 · Accesswire · Bausch Health Companies
    Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
    11.04.24 · Accesswire · Bausch Health Companies
    Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
    03.04.24 · Accesswire · Bausch Health Companies
    Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
    02.04.24 · Accesswire · Bausch Health Companies
    Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
    06.03.24 · Accesswire · Bausch Health Companies
    New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
    05.03.24 · Accesswire · Bausch Health Companies